Vancomycin AUC Dosing in Acute Kidney Injury
A 68-year-old man (80 kg, serum creatinine 2.1 mg/dL, estimated CrCl 30 mL/min by Cockcroft-Gault) is admitted with MRSA bacteremia. The team orders vancomycin 15 mg/kg IV q12h (1200 mg). After the third dose, trough is 28 mcg/mL and a single peak drawn 2 h post-infusion is 42 mcg/mL. The nephrologist wants to continue the same dose because 'the trough is what matters.' The pharmacy has AUC-based monitoring capability using two levels. The patient's weight is stable and he is not on dialysis.
1. Calculate the AUC24 from the available levels and assess whether the current regimen is appropriate for a serious MRSA infection (target AUC24 400-600 mg·h/L).
Read the worked answer
Using a two-point trapezoidal/linear-log approach: with trough 28 and peak 42, the elimination estimate gives a half-life of roughly 6-8 h in this patient. A reasonable approximation of AUC24 for q12h dosing is AUC per interval × 2. A rough estimate: AUC(0-12) ≈ (Cmax + Cmin)/2 × dosing interval is too crude; better is to use the log-linear method: k = ln(42/28)/(time between levels). If the peak was 2 h post-infusion and trough 12 h post-dose, Δt ≈ 10 h, k = ln(1.5)/10 = 0.0405/h, t½ ≈ 17 h - implausibly long, indicating the 'peak' was actually near-distribution or the trough was drawn early. Regardless, a trough of 28 mcg/mL is far above the 10-15 (or 15-20 for severe) target, and AUC24 is almost certainly >600. Conclusion: regimen is supratherapeutic; hold the next dose, recheck levels, and reduce to ~15-20 mg/kg q24h with AUC-guided adjustment. Acknowledge that a single post-distribution level plus a trough is needed for accurate AUC; the levels here are inconsistent, so redraw levels correctly before final dose calculation.
2. The nephrologist argues troughs are the standard. How should the pharmacist respond, and what monitoring parameters should be added?
Read the worked answer
The pharmacist should cite the 2020 IDSA/ASHP/SIDP vancomycin guideline: for serious MRSA infections, AUC24/MIC-guided dosing (target 400-600) is preferred over trough-only monitoring because troughs correlate poorly with AUC and increase nephrotoxicity risk when >15-20. In AKI, trough-only monitoring overestimates exposure because accumulation is nonlinear. Add: daily SCr and urine output, urinalysis, concurrent nephrotoxins (NSAIDs, contrast, piperacillin-tazobactam), and audiometry/vestibular symptoms. Document the recommendation, the rationale, and the plan to redraw levels (trough before 4th dose, peak 1-2 h post-infusion after steady state).
3. If the patient's renal function worsens (SCr 3.5 mg/dL), what is the appropriate next step for vancomycin dosing?
Read the worked answer
Hold vancomycin, obtain a level, and reassess. With SCr 3.5, CrCl is roughly 15-18 mL/min; standard nomograms are unreliable. Use a Bayesian or AUC-guided approach, extend interval to q24-48h, and consider whether the infection is controlled. If levels remain high, consider alternative MRSA therapy (daptomycin if not pneumonia, linezolid) after culture/susceptibility review. Monitor for ototoxicity and nephrotoxicity; do not simply reduce dose without levels.